These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 35999650)

  • 1. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
    JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
    Razvi Y; Ioannou A; Patel RK; Chacko L; Karia N; Riefolo M; Porcari A; Rauf MU; Starr N; Ganesananthan S; Blakeney I; Kaza N; Filisetti S; Bolhuis RE; Rowczenio D; Gilbertson J; Hutt D; Mahmood S; Lachmann HJ; Wechalekar AD; Kotecha T; Knight DS; Coghlan JG; Petrie A; Whelan CJ; Venneri L; Martinez-Naharro A; Hawkins P; Fontana M; Gillmore JD
    Eur J Heart Fail; 2024 Feb; 26(2):383-393. PubMed ID: 37953725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Madhani A; Sabogal N; Massillon D; Paul LD; Rodriguez C; Fine D; Helmke S; Winburn M; Kurian D; Raiszadeh F; Teruya S; Cohn E; Einstein AJ; Miller EJ; Connors LH; Maurer MS; Ruberg FL
    J Am Heart Assoc; 2023 Aug; 12(15):e028973. PubMed ID: 37486082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
    Lyng CS; Gude E; Hodt A; Knudsen EC
    Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS.
    Caponetti AG; Rapezzi C; Gagliardi C; Milandri A; Dispenzieri A; Kristen AV; Wixner J; Maurer MS; Garcia-Pavia P; Tournev I; Planté-Bordeneuve V; Chapman D; Amass L;
    JACC Heart Fail; 2021 Oct; 9(10):736-746. PubMed ID: 34391735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of genetic study in elderly patients with transthyretin cardiac amyloidosis.
    Gallego Delgado M; Gayán Ordás J; Eiros R; García Berrocal B; Sánchez PL; Villacorta E
    Med Clin (Barc); 2023 Nov; 161(9):382-385. PubMed ID: 37532616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
    Antonopoulos AS; Panagiotopoulos I; Kouroutzoglou A; Koutsis G; Toskas P; Lazaros G; Toutouzas K; Tousoulis D; Tsioufis K; Vlachopoulos C
    Eur J Heart Fail; 2022 Sep; 24(9):1677-1696. PubMed ID: 35730461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
    Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
    Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; Davies DR; Scott CG; Fayyaz AU; Askew JW; McKie PM; Noseworthy PA; Johnson GB; Dunlay SM; Borlaug BA; Chareonthaitawee P; Roger VL; Dispenzieri A; Grogan M; Redfield MM
    JAMA Cardiol; 2021 Nov; 6(11):1267-1274. PubMed ID: 34431962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Ruberg FL; Blaner WS; Chiuzan C; Connors LH; Einstein AJ; Fine D; Helmke S; Kurian D; Pandey S; Raiszadeh F; Rodriguez C; Sabogal N; Teruya S; Winburn M; Chung WK; Cohn E; Miller EJ; Kelly JW; Maurer MS
    J Am Heart Assoc; 2023 Apr; 12(8):e028534. PubMed ID: 37066788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.
    Ungericht M; Wanschitz J; Kroiss AS; Röcken C; Schuetz T; Messner M; Zaruba MM; Loescher WN; Poelzl G
    J Nucl Cardiol; 2023 Aug; 30(4):1420-1426. PubMed ID: 35581484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?
    Aus dem Siepen F; Hein S; Prestel S; Baumgärtner C; Schönland S; Hegenbart U; Röcken C; Katus HA; Kristen AV
    Clin Res Cardiol; 2019 Dec; 108(12):1324-1330. PubMed ID: 30953182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, clinical characteristics, and diagnostic approach in transthyretin amyloid cardiomyopathy: The Kumamoto Cardiac Amyloidosis Survey.
    Takashio S; Tokitsu T; Matsukawa M; Sakaino N; Fujimoto K; Sakamoto T; Noda K; Tsunoda R; Misumi I; Hirai N; Doi H; Koide S; Mizuno Y; Hirose T; Kurokawa H; Kajiwara I; Ohba K; Miyamoto S; Araki S; Yamamoto E; Matsushita K; Ueda M; Tsujita K;
    J Cardiol; 2022 Jul; 80(1):49-55. PubMed ID: 35078683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
    Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
    Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neurological manifestations of ATTR amyloidosis].
    Pernice HF; Hahn K
    Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT.
    Nativi-Nicolau J; Judge DP; Hoffman JE; Gundapaneni B; Keohane D; Sultan MB; Grogan M
    ESC Heart Fail; 2021 Oct; 8(5):3875-3884. PubMed ID: 34432383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transthyretin amyloidosis: Putting myopathy on the map.
    Pinto MV; Milone M; Mauermann ML; Dyck PJB; Alhammad R; McPhail ED; Grogan M; Liewluck T
    Muscle Nerve; 2020 Jan; 61(1):95-100. PubMed ID: 31587306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.